

**Amendments to the Claims**

Please amend Claims 1-8 and 11.

Please add new Claims 14-20.

The Claim Listing below will replace all prior versions of the claims in the application:

**Claim Listing**

1. (Currently Amended) A method of treating TNF $\alpha$ -mediated cachexia associated with cancer in a human comprising administering to the human an effective ~~TNF-inhibiting~~ TNF $\alpha$ -inhibiting amount of an ~~anti-TNF~~ anti-TNF $\alpha$  chimeric antibody, wherein said ~~anti-TNF~~ anti-TNF $\alpha$  chimeric antibody competitively inhibits binding of ~~TNF~~ human TNF $\alpha$  to anti-TNF $\alpha$  chimeric monoclonal antibody cA2.
2. (Currently Amended) A method of treating TNF $\alpha$ -mediated cachexia associated with cancer in a human comprising administering to the human an effective ~~TNF-inhibiting~~ TNF $\alpha$ -inhibiting amount of an ~~anti-TNF~~ anti-TNF $\alpha$  chimeric antibody, wherein said ~~anti-TNF~~ anti-TNF $\alpha$  chimeric antibody binds to at least one epitope included in amino acids between 87-108 or both 59-80 and 87-108 of SEQ ID NO.:1 of hTNF, as determined by Geysen epitope mapping comprising use of TNF decapeptide pins which overlap at every second amino acid and synthesized on polyethylene pins.
3. (Currently Amended) A method of treating TNF $\alpha$ -mediated cachexia associated with cancer in a human comprising administering to the human an effective ~~TNF-inhibiting~~ TNF $\alpha$ -inhibiting amount of ~~chimeric anti-TNF~~ anti-TNF $\alpha$  chimeric monoclonal antibody cA2.
4. (Currently Amended) A method for treating TNF $\alpha$ -mediated cachexia associated with cancer in a human comprising administering to the human at least one anti-TNF $\alpha$  chimeric monoclonal antibody cA2, or a ~~TNF-binding~~ TNF $\alpha$ -binding fragment thereof.

5. (Currently Amended) A method of treating TNF $\alpha$ -mediated cachexia associated with cancer in a human comprising administering to the human an effective ~~TNF-inhibiting~~ TNF $\alpha$ -inhibiting amount of an ~~anti-TNF~~ anti-TNF $\alpha$  chimeric antibody, wherein said ~~anti-TNF~~ anti-TNF $\alpha$  chimeric antibody comprises an IgG1 constant region and competitively inhibits binding of ~~TNF~~ human TNF $\alpha$  to anti-TNF $\alpha$  chimeric monoclonal antibody cA2.
6. (Currently Amended) A method of treating TNF $\alpha$ -mediated cachexia associated with cancer in a human comprising administering to the human an effective ~~TNF-inhibiting~~ TNF $\alpha$ -inhibiting amount of an ~~anti-TNF~~ anti-TNF $\alpha$  chimeric antibody, wherein said ~~anti-TNF~~ anti-TNF $\alpha$  chimeric antibody comprises an IgG1 constant region and binds to at least one epitope included in amino acids between 87-108 or both 59-80 and 87-108 of SEQ ID NO.:1 of hTNF, as determined by Geysen epitope mapping comprising use of TNF decapeptide pins which overlap at every second amino acid and synthesized on polyethylene pins.
7. (Currently Amended) A method of treating TNF $\alpha$ -mediated cachexia associated with cancer in a human comprising administering to the human an effective ~~TNF-inhibiting~~ TNF $\alpha$ -inhibiting amount of an ~~anti-TNF~~ anti-TNF $\alpha$  chimeric antibody, wherein said ~~anti-TNF~~ anti-TNF $\alpha$  chimeric antibody comprises a non-human variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NO.:3 and SEQ ID NO.:5.
8. (Currently Amended) A method of treating TNF $\alpha$ -mediated cachexia associated with cancer in a human comprising administering to the human an effective ~~TNF-inhibiting~~ TNF $\alpha$ -inhibiting amount of an ~~anti-TNF~~ anti-TNF $\alpha$  chimeric antibody, wherein said ~~anti-TNF~~ anti-TNF $\alpha$  chimeric antibody comprises an IgG1 human constant region and a non-human variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NO.:3 and SEQ ID NO.:5.

9. (Original) The method of Claim 7 wherein the non-human variable region comprises a polypeptide encoded by a nucleic acid sequence selected from the group consisting of SEQ ID NO.:2 and SEQ ID NO.:4.
10. (Original) The method of Claim 8 wherein the non-human variable region comprises a polypeptide encoded by a nucleic acid sequence selected from the group consisting of SEQ ID NO.:2 and SEQ ID NO.:4.
11. (Currently Amended) A method of treating TNF $\alpha$ -mediated cachexia associated with cancer in a human comprising administering to the human an effective ~~TNF-inhibiting~~ TNF $\alpha$ -inhibiting amount of an ~~anti-TNF~~ anti-TNF $\alpha$  chimeric antibody, wherein said ~~anti-TNF~~ anti-TNF $\alpha$  chimeric antibody has epitopic specificity identical to monoclonal antibody cA2.
- 12.-13. (Canceled)
14. (New) The method of Claim 1, wherein said anti-TNF $\alpha$  chimeric antibody is administered to the human by means of parenteral administration.
15. (New) The method of Claim 1, wherein said anti-TNF $\alpha$  chimeric antibody is administered to the human by means of intravenous administration, subcutaneous administration or intramuscular administration.
16. (New) The method of Claim 1, wherein said anti-TNF $\alpha$  chimeric antibody is administered to the human via the lung.
17. (New) The method of Claim 1, wherein said anti-TNF $\alpha$  chimeric antibody is administered to the human orally.
18. (New) The method of Claim 1, wherein said TNF $\alpha$ -inhibiting amount of the anti-TNF $\alpha$

chimeric antibody comprises a single or divided dose of about 0.1 - 50 mg/kg.

19. (New) The method of Claim 18, wherein said single or divided dose is selected from the group consisting of: about a 0.1 - 1 mg/kg dose, about a 1.0 - 5 mg/kg dose, about a 5 - 10 mg/kg dose and about a 10 - 20 mg/kg dose.
20. (New) The method of Claim 1, further comprising administering to the human an effective amount of a therapeutic agent selected from the group consisting of: radiotherapeutics, cytotoxic drugs, monoclonal antibodies, chimeric antibodies, antibody fragments, antibody regions, lymphokines, cytokines, hemopoietic growth factors and immunoglobulins.